80,096 Shares in Progyny, Inc. (NASDAQ:PGNY) Purchased by Moore Capital Management LP

Moore Capital Management LP acquired a new stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 80,096 shares of the company's stock, valued at approximately $1,382,000. Moore Capital Management LP owned approximately 0.09% of Progyny as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC raised its position in Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. GAMMA Investing LLC raised its position in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after acquiring an additional 1,526 shares in the last quarter. Caitlin John LLC raised its position in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after acquiring an additional 3,183 shares in the last quarter. Finally, Natixis bought a new position in Progyny during the fourth quarter valued at approximately $69,000. Institutional investors own 94.93% of the company's stock.

Progyny Price Performance

Shares of Progyny stock traded up $0.35 during midday trading on Friday, hitting $22.30. The company had a trading volume of 1,167,007 shares, compared to its average volume of 1,713,249. The business's 50 day simple moving average is $22.03 and its two-hundred day simple moving average is $19.68. The stock has a market cap of $1.91 billion, a PE ratio of 38.45, a P/E/G ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The firm's quarterly revenue was up 16.5% on a year-over-year basis. On average, sell-side analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Bank of America raised their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a research report on Monday, March 31st. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Finally, Canaccord Genuity Group dropped their price target on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $23.45.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.